Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 1;26(R1):R45-R50.
doi: 10.1093/hmg/ddx228.

Genetics of age-related macular degeneration (AMD)

Affiliations
Review

Genetics of age-related macular degeneration (AMD)

Margaret M DeAngelis et al. Hum Mol Genet. .

Erratum in

  • Genetics of age-related macular degeneration (AMD).
    DeAngelis MM, Owen LA, Morrison MA, Morgan DJ, Li M, Shakoor A, Vitale A, Iyengar S, Stambolian D, Kim IK, Farrer LA. DeAngelis MM, et al. Hum Mol Genet. 2017 Oct 1;26(R2):R246. doi: 10.1093/hmg/ddx343. Hum Mol Genet. 2017. PMID: 28977452 Free PMC article. No abstract available.

Abstract

Age-related macular degeneration (AMD) is a progressive blinding disease and represents the leading cause of visual impairment in the aging population. AMD affects central vision which impairs one's ability to drive, read and recognize faces. There is no cure for this disease and current treatment modalities for the exudative form of the disease require repeated intravitreal injections which may be painful, are incompletely efficacious, and represent a significant treatment burden for both the patient and physician. As such, AMD represents a significant and important clinical problem.It is anticipated that in three years' time, 196 million individuals will be affected with AMD. Over 250 billion dollars per year are spent on care for AMD patients in the US. Over half of the heritability is explained by two major loci, thus AMD is considered the most well genetically defined of the complex disorders. A recent GWAS on 43,566 subjects identified novel loci and pathways associated with AMD risk, which has provided an excellent platform for additional functional studies. Genetic variants have been investigated, particularly with respect to anti-VEGF treatment, however to date, no pharmacogenomic associations have been consistently identified across these studies. It may be that if the goal of personalized medicine is to be realized and biomarkers are to have predictive value for determining the magnitude of risk for AMD at the genetic level, one will need to examine the relationships between these pathways across disease state and relative to modifiable risk factors such as hypertension, smoking, body mass index, and hypercholesterolemia. Further studies investigating protective alleles in populations with low AMD prevalence may lead to this goal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Predictive, preventive, personalized medicine. Model for approaching the integrative analysis of patient phenotype in the context of individual ‘omic’, environmental and experimental data. The significance of each of these factors for an individual patient may vary as demonstrated.

References

    1. Wong W.L., Su X., Li X., Cheung C.M.G., Klein R., Cheng C.-Y., Wong T.Y. (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health, 2, e106–e116. - PubMed
    1. Rein D.B., Wittenborn J.S., Zhang X., Honeycutt A.A., Lesesne S.B., Saaddine J. (2009) Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatment. Arch. Ophthalmol., 127, 533–540. - PubMed
    1. Aging N.I. (2011) Alzheimer’s disease fact sheet. National Institute on Aging. https://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-s...; date last accessed June 6, 2017.
    1. Age-Related Macular Degeneration: Facts & Figures (2015) BrightFocus Foundation.http://www.brightfocus.org/macular/article/age-related-macular-facts-fig...; date last accessed June 6, 2017.
    1. Klein R., Klein B.E., Linton K.L. (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology, 99, 933–943. - PubMed

Publication types